

Special Issue

Advances in Precision Oncology for Thyroid Carcinoma: Integrating Artificial Intelligence, Genomics and Molecular Diagnostics

Message from the Guest Editor

Thyroid carcinoma, particularly differentiated thyroid carcinoma (DTC), has become increasingly prevalent, with diverse clinical behaviors ranging from indolent nodules to aggressive, treatment-resistant variants. As traditional risk stratification approaches face limitations in capturing the underlying tumor biology, there is a growing need for precision medicine frameworks incorporating genomic, radiologic, and molecular data. This Special Issue will explore recent advances in artificial intelligence (AI), next-generation sequencing (NGS), and multi-omics diagnostics which are transforming the landscape of thyroid cancer diagnosis, prognostication, and management.

Guest Editor

Dr. Kyoung Sik Park

Department of Surgery, Konkuk University Medical Centre, Konkuk University School of Medicine, 120 Neungdong-ro, Gwangjin-gu, Seoul 143-729, Republic of Korea

Deadline for manuscript submissions

closed (30 June 2026)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



mdpi.com/si/241592

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.2 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2026).